LISATA THERAPEUTICS, INC.

LISATA THERAPEUTICS, INC., operating under the Pharmaceutical Preparations SIC framework, develops and markets specialized therapeutic formulations designed for commercial and institutional healthcare buyers, including hospitals and integrated delivery networks focused on advancing patient care through precision dosing; the company’s research-driven pipeline emphasizes compliance-ready manufacturing processes and regulatory approvals to support physicians prescribing its intellectual property–bearing treatments. Known as CIK 320017, the firm’s business model leans on long-term contracts and partnerships, aiming to provide consistent, quality-tested pharmaceuticals to clinics and pharmacies that demand regulated, scalable production, yet it faces industry-wide material risks such as evolving FDA guidance, reimbursement pressures, and supply-chain volatility that can delay product launches or complicate inventory management. The most recent public disclosure, a Form 10-Q filed in November 1999, highlights these ongoing operational and compliance considerations, so investors may wish to view live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025